Prestige Consumer Healthcare Q3 2026 revenue at USD 283.4 million, down 2.4%

Reuters02-05 19:01

Prestige Consumer Healthcare Q3 2026 revenue at USD 283.4 million, down 2.4%

Prestige Consumer Healthcare Inc. reported revenue of USD 283.4 million for the third quarter (Q3) of fiscal 2026, exceeding its outlook. Diluted earnings per share $(EPS)$ for Q3 were USD 0.97, while adjusted diluted EPS stood at USD 1.14. For the nine months ended December 31, 2025, the company reported year-to-date revenue in line with its narrowed fiscal 2026 outlook of approximately USD 1.1 billion, with an anticipated organic revenue decline of about 3 percent for the year. Adjusted diluted EPS for fiscal 2026 is expected to be approximately USD 4.54, with free cash flow projected at USD 245 million or more. During the quarter, Prestige Consumer Healthcare Inc. repurchased approximately 0.8 million shares. The company also announced the successful completion of its acquisition of eye care supplier Pillar5 Pharma, Inc. in December. Management highlighted the benefits of its diverse business model and strong financial profile, noting that these contributed to exceeding revenue expectations and delivering solid profitability in Q3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prestige Consumer Healthcare Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649543-en) on February 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609376162?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609376162","market":"fut","top_or_hot":-1,"title":"Prestige Consumer Healthcare Q3 2026 revenue at USD 283.4 million, down 2.4%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Prestige Consumer Healthcare Q3 2026 revenue at USD 283.4 million, down 2.4%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Prestige Consumer Healthcare Inc. reported revenue of USD 283.4 million for the third quarter (Q3) of fiscal 2026, exceeding its outlook. Diluted earnings per share <a href=\"https://laohu8.com/S/EPS\">$(EPS)$</a> for Q3 were USD 0.97, while adjusted diluted EPS stood at USD 1.14. For the nine months ended December 31, 2025, the company reported year-to-date revenue in line with its narrowed fiscal 2026 outlook of approximately USD 1.1 billion, with an anticipated organic revenue decline of about 3 percent for the year. Adjusted diluted EPS for fiscal 2026 is expected to be approximately USD 4.54, with free cash flow projected at USD 245 million or more. During the quarter, Prestige Consumer Healthcare Inc. repurchased approximately 0.8 million shares. The company also announced the successful completion of its acquisition of eye care supplier Pillar5 Pharma, Inc. in December. Management highlighted the benefits of its diverse business model and strong financial profile, noting that these contributed to exceeding revenue expectations and delivering solid profitability in Q3.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prestige Consumer Healthcare Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649543-en) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prestige Consumer Healthcare Q3 2026 revenue at USD 283.4 million, down 2.4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrestige Consumer Healthcare Q3 2026 revenue at USD 283.4 million, down 2.4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Prestige Consumer Healthcare Q3 2026 revenue at USD 283.4 million, down 2.4%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Prestige Consumer Healthcare Inc. reported revenue of USD 283.4 million for the third quarter (Q3) of fiscal 2026, exceeding its outlook. Diluted earnings per share <a href=\"https://laohu8.com/S/EPS\">$(EPS)$</a> for Q3 were USD 0.97, while adjusted diluted EPS stood at USD 1.14. For the nine months ended December 31, 2025, the company reported year-to-date revenue in line with its narrowed fiscal 2026 outlook of approximately USD 1.1 billion, with an anticipated organic revenue decline of about 3 percent for the year. Adjusted diluted EPS for fiscal 2026 is expected to be approximately USD 4.54, with free cash flow projected at USD 245 million or more. During the quarter, Prestige Consumer Healthcare Inc. repurchased approximately 0.8 million shares. The company also announced the successful completion of its acquisition of eye care supplier Pillar5 Pharma, Inc. in December. Management highlighted the benefits of its diverse business model and strong financial profile, noting that these contributed to exceeding revenue expectations and delivering solid profitability in Q3.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prestige Consumer Healthcare Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649543-en) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJJMRZ35.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL4m6QGM:1","article_id":"2609376162","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609376162","pubTimestamp":1770289264,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Prestige Consumer Healthcare Inc. reported revenue of USD 283.4 million for the third quarter  of fiscal 2026, exceeding its outlook. Diluted earnings per share  for Q3 were USD 0.97, while adjusted diluted EPS stood at USD 1.14. For the nine months ended December 31, 2025, the company reported year-to-date revenue in line with its narrowed fiscal 2026 outlook of approximately USD 1.1 billion, with an anticipated organic revenue decline of about 3 percent for the year. Adjusted diluted EPS for fiscal 2026 is expected to be approximately USD 4.54, with free cash flow projected at USD 245 million or more. During the quarter, Prestige Consumer Healthcare Inc. repurchased approximately 0.8 million shares. The company also announced the successful completion of its acquisition of eye care supplier Pillar5 Pharma, Inc. in December. Management highlighted the benefits of its diverse business model and strong financial profile, noting that these contributed to exceeding revenue expectations an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0079474960.USD":"联博美国增长基金A","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","PBH":"普雷斯蒂奇","VRTX":"福泰制药","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4532":"文艺复兴科技持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"translate_title":"Prestige Consumer Healthcare 2026年第三季度收入为2.834亿美元，下降2.4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PBH":0.9,"VRTX":0.9},"content_text":"Prestige Consumer Healthcare Q3 2026 revenue at USD 283.4 million, down 2.4%\n    \n\n        Prestige Consumer Healthcare Inc. reported revenue of USD 283.4 million for the third quarter (Q3) of fiscal 2026, exceeding its outlook. Diluted earnings per share $(EPS)$ for Q3 were USD 0.97, while adjusted diluted EPS stood at USD 1.14. For the nine months ended December 31, 2025, the company reported year-to-date revenue in line with its narrowed fiscal 2026 outlook of approximately USD 1.1 billion, with an anticipated organic revenue decline of about 3 percent for the year. Adjusted diluted EPS for fiscal 2026 is expected to be approximately USD 4.54, with free cash flow projected at USD 245 million or more. During the quarter, Prestige Consumer Healthcare Inc. repurchased approximately 0.8 million shares. The company also announced the successful completion of its acquisition of eye care supplier Pillar5 Pharma, Inc. in December. Management highlighted the benefits of its diverse business model and strong financial profile, noting that these contributed to exceeding revenue expectations and delivering solid profitability in Q3.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prestige Consumer Healthcare Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649543-en) on February 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609376162","isCrawlerRequest":true}